文献速递湿疹皮炎与荨麻疹

荷兰特应性皮炎患者口服免疫抑制剂的使用情况

Use of oral immunosuppressive drugs in the treatment of atopic dermatitis in the Netherlands.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2018-01-01

结果显示1.4%的患者使用环孢素A、甲氨蝶呤、硫唑嘌呤或麦考酚酸,甲氨蝶呤最常用,环孢素A处方减少而甲氨蝶呤增加。

要点

  • 65943例特应性皮炎患者中943例(1.4%)使用口服免疫抑制剂。
  • 甲氨蝶呤最常用,其次为硫唑嘌呤和环孢素A。
  • 研究期间环孢素A处方减少,甲氨蝶呤处方增加。

核心结论

  • 在该研究人群中,1.4%的特应性皮炎患者在5年期间使用口服免疫抑制剂治疗湿疹。
  • 甲氨蝶呤是荷兰治疗特应性皮炎最常用的系统性药物。

研究设计与样本

  • 基于WHO解剖治疗化学(ATC)编码的算法识别特应性皮炎患者。
  • 评估2012年1月1日至2017年1月1日期间特应性皮炎患者的口服免疫抑制剂处方。

主要发现

  • 基于算法共选出65943例特应性皮炎患者。
  • 943例特应性皮炎患者(1.4%)使用环孢素A、甲氨蝶呤、硫唑嘌呤或麦考酚酸。
  • 甲氨蝶呤最常用,其次为硫唑嘌呤和环孢素A。
  • 药物转换少见。
  • 评估期间环孢素A处方减少,同时甲氨蝶呤处方增加。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although atopic dermatitis (AD) is a very common skin disease, data on the percentage of patients with really difficult-to-treat AD are scarce. From socio-economic perspective, it is important to have more insight into these numbers, as new very effective, but expensive, treatment options will be available in the near future for difficult-to-treat AD. Estimating the number of patients with AD using oral immunosuppressive drugs can give an impression of the percentage of difficult-to-treat patients in the total AD population. OBJECTIVE: To give an overview of the use of oral immunosuppressive drugs in patients with AD in the Netherlands. METHODS: Prescription data of oral immunosuppressive drugs in the Netherlands were extracted from a pharmaceutical database (NControl) containing data of 557 million prescriptions and 7.2 million patients. An algorithm, based on the WHO Anatomical Therapeutic Chemical (ATC) codes, was used to identify patients with AD. The prescription of oral immunosuppressive drugs in patients with AD between 1 January 2012 and 1 January 2017 was evaluated. RESULTS: Based on the algorithm, 65 943 patients with AD were selected. 943 patients with AD (1.4%) used cyclosporine A, methotrexate, azathioprine or mycophenolic acid. Methotrexate was most commonly used, followed by azathioprine and cyclosporine A. A switch in medication was rarely seen. In the evaluation period, a decrease in the prescription of cyclosporine A was seen, together with an increase in the prescription of methotrexate. In 31% of the patients who stopped treatment, the discontinuation took place within the first months of treatment. CONCLUSION: In this study population, 1.4% of the patients with AD used oral immunosuppressive drugs for their eczema in a 5-year period. Methotrexate was the most commonly used systemic drug in the Netherlands for the treatment of AD.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Garritsen FM, van den Heuvel JM, Bruijnzeel-Koomen CAFM, et al. Use of oral immunosuppressive drugs in the treatment of atopic dermatitis in the Netherlands. J Eur Acad Dermatol Venereol. 2018. PMID: 29485224. doi:10.1111/jdv.14896

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。